Compare Bath & Body Works Inc (BBWI) vs Biogen Inc (BIIB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bath & Body Works Inc vs Biogen Inc — how do they compare? Bath & Body Works Inc trades at $18.9 (market cap $3.81B), while Biogen Inc trades at $202.7 (market cap $30.13B). The key difference: Biogen Inc is far larger — about 7.9× Bath & Body Works Inc's market cap, and Bath & Body Works Inc pays a 4.24% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| BBWI | BIIB | |
|---|---|---|
Market Cap | $3.81B | $30.13B |
Sector | Consumer Cyclical | Health |
52-Week High | $31.87 | $216.63 |
52-Week Low | $14.85 | $128.93 |
Enterprise Value | $7.70B | $37.20B |
Dividend Yield | 4.24% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bath & Body Works Inc
Bath & Body Works is a specialty home fragrance and fragrant body care retailer operating under the Bath & Body Works, C.O. Bigelow, and White Barn brands. The company generates most of its business in North America, with less than 5% of sales from international markets in fiscal 2021. For fiscal 2021, 72% of sales stemmed from the brick-and-mortar network (which is composed of more than 1,700 retail stores), up from 65% in 2020, as consumer shopping patterns began to return to normal. Future growth is expected from store reformatting, digital and international channels, as well as new category expansion.
Read more on BBWI →About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →
